Transition Therapeutics Appoints Carl Damiani as Chief Operating Officer
Transition Therapeutics Inc. Chairman and Chief Executive Officer, Dr. Tony Cruz announced that Carl Damiani has been appointed to the role of Chief Operating Officer of Transition.
"This appointment reflects Mr. Damiani's broader leadership role in overseeing Transition employees and operations in Toronto, San Francisco and Ireland, as well as advancing our late stage neuropsychiatric drug candidate, ELND005, for AD patients, the phase 2 diabetes drug candidate TT-401 partnered with Lilly, and growing our pipeline with assets acquired from pharma partners", said Dr. Tony Cruz, Chairman and Chief Executive Officer of Transition.
Since joining Transition in 2003, Mr. Damiani has held the roles of Vice-President of Business Development and Director of Business Development.
Most read news
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.